Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × sintilimab × Clear all
NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡